Final Share Purchase Plan Allotment
Filed with ASX · · 3 pages · English
Summary by 6ix AI
Imugene Ltd has announced the completion of its Share Purchase Plan, which closed recently. The plan raised a total amount from the issuance of new shares at a specified price. Shareholder approval for the new shares was obtained at a recent extraordinary general meeting. The new shares will be issued shortly after the announcement. The CEO expressed gratitude to investors for their support of the company.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from Imugene
- Appendix 4E and Annual Report
- Imugene Capital Raising Presentation
- Imugene Completes $22.5M Placement and c.$15M SPP
- Imugene Announces Outstanding Response Rates from the Phase 1b Trial of the Azer-cel Allogeneic CAR T in 3L+ DLBCL
- Two Additional Complete Responses in azer-cel Ph1b trial
Later from Imugene
- S&P DJI Announces September 2025 Quarterly Rebalance
- Strategic Collaboration with JW Therapeutics
- Imugene and JW Therapeutics Announce a Collaboration to Advance onCARlytics and Carteyva® Combination in Solid Tumours
- FDA Supports Strategy Toward Registration for Azer-cel
- Quarterly Activities/Appendix 4C Cash Flow Report
Follow Imugene into a list and get an email when it puts out news.
Follow Imugene